Physician profile
Michael S Obrien
NPI 1164496238
$4,540.01
in general payments reported to CMS, 2019-2025
32 companies · $445 in 2025
The $445 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $383 · 2021: $511 · 2022: $801 · 2023: $1,199 · 2024: $195 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189 · Travel and Lodging: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.09 |
| Travel and Lodging | $650.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,294.80 | 2019-2025 | Iconix, Alphavent |
| Pylant Medical | $778.99 | 2019-2023 | |
| Arthrex, INC. | $547.48 | 2023 | |
| Encore Medical, LP | $225.87 | 2023 | Djo Surgical |
| Pacira Therapeutics, INC. | $167.17 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $144.89 | 2022 | |
| Dynasplint Systems INC. | $139.82 | 2019-2024 | Dynasplint |
| Endo Pharmaceuticals INC. | $122.75 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $117.44 | 2020-2025 | Zilretta, Iovera, Exparel |
| Horizon Therapeutics Plc | $106.58 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $96.72 | 2019-2022 | |
| Bioventus LLC | $91.63 | 2021-2025 | Durolane |
| Vertex Pharmaceuticals Incorporated | $90.17 | 2024-2025 | |
| Smith+Nephew, INC. | $72.94 | 2025 | Firstpass, Coblation, Accu-Pass |
| Linvatec Corporation | $50.19 | 2024 | Biobrace 23mm |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acumed LLC | $49.14 | 2021 | |
| Merck Sharp & Dohme LLC | $46.38 | 2019 | |
| Nabriva Therapeutics, Plc | $45.09 | 2021-2022 | |
| Sonex Health, INC. | $42.64 | 2021 | |
| Anika Therapeutics, INC. | $42.51 | 2025 | Integrity Implant |
| Convatec INC. | $36.28 | 2021-2023 | |
| Baudax Bio INC. | $29.50 | 2020-2021 | |
| Organogenesis INC. | $27.34 | 2021-2024 | |
| Innovation Technologies INC | $27.17 | 2025 | Irrisept |
| Zimmer Biomet Holdings, INC. | $26.83 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Davol INC. | $26.05 | 2023 | Channel Drain |
| Axogen | $25.17 | 2021 | |
| Depuy Synthes Sales INC. | $20.15 | 2020 | |
| Fidia Pharma USA INC. | $15.78 | 2019 | |
| Lilly USA, LLC | $15.57 | 2023 | Mounjaro |
| Melinta Therapeutics, LLC | $11.72 | 2019 | |
| Orthofix Medical, INC. | $5.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.